Patrick Lamy Akero Therapeutics, Inc. (AKRO) insider trading activity

AKRO Quotes by TradingView

Patrick Lamy is Senior VP, Commercial Strategy of Akero Therapeutics, Inc.. Currently has a direct ownership of 29,891 shares of AKRO, which is worth approximately $1.55 Million. The most recent transaction as insider was on Jul 01, 2025, when has been sold 2,000 shares (Common Stock) at a price of $52.88 per share, resulting in proceeds of $105,760. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 29.9K
10.75% 3M change
59.14% 12M change
Total Value Held $1.55 Million

Patrick Lamy Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jul 01 2025
SELL
Open market or private sale
$105,760 $52.88 p/Share
2,000 Reduced 6.27%
29,891 Common Stock
Jun 30 2025
BUY
Grant, award, or other acquisition
$4,606 $23.87 p/Share
193 Added 0.6%
31,891 Common Stock
Jun 20 2025
SELL
Open market or private sale
$47,766 $54.59 p/Share
875 Reduced 2.69%
31,698 Common Stock
Jun 16 2025
SELL
Open market or private sale
$108,920 $54.46 p/Share
2,000 Reduced 5.78%
32,573 Common Stock
Jun 16 2025
BUY
Exercise of conversion of derivative security
$39,740 $19.87 p/Share
2,000 Added 5.47%
34,573 Common Stock
Jun 10 2025
SELL
Open market or private sale
$49,626 $54.0 p/Share
919 Reduced 2.74%
32,573 Common Stock
Jun 02 2025
SELL
Open market or private sale
$201,200 $50.3 p/Share
4,000 Reduced 10.67%
33,492 Common Stock
Jun 02 2025
BUY
Exercise of conversion of derivative security
$79,480 $19.87 p/Share
4,000 Added 9.64%
37,492 Common Stock
May 22 2025
SELL
Open market or private sale
$200,000 $50.0 p/Share
4,000 Reduced 10.67%
33,492 Common Stock
May 22 2025
BUY
Exercise of conversion of derivative security
$177,480 $44.37 p/Share
4,000 Added 9.64%
37,492 Common Stock
May 07 2025
SELL
Open market or private sale
$340,320 $42.54 p/Share
8,000 Reduced 19.28%
33,492 Common Stock
May 07 2025
BUY
Exercise of conversion of derivative security
$158,960 $19.87 p/Share
8,000 Added 16.16%
41,492 Common Stock
Mar 03 2025
SELL
Open market or private sale
$48,090 $48.09 p/Share
1,000 Reduced 2.9%
33,492 Common Stock
Mar 03 2025
BUY
Exercise of conversion of derivative security
$19,870 $19.87 p/Share
1,000 Added 2.82%
34,492 Common Stock
Jan 27 2025
SELL
Open market or private sale
$285,150 $57.03 p/Share
5,000 Reduced 12.99%
33,492 Common Stock
Jan 27 2025
BUY
Exercise of conversion of derivative security
$79,480 $19.87 p/Share
4,000 Added 9.41%
38,492 Common Stock
Dec 31 2024
BUY
Grant, award, or other acquisition
$4,607 $19.69 p/Share
234 Added 0.67%
34,492 Common Stock
Dec 16 2024
SELL
Open market or private sale
$29,130 $29.13 p/Share
1,000 Reduced 2.84%
34,258 Common Stock
Dec 16 2024
BUY
Grant, award, or other acquisition
-
17,400 Added 33.04%
35,258 Common Stock
Dec 10 2024
SELL
Open market or private sale
$28,480 $30.79 p/Share
925 Reduced 4.92%
17,858 Common Stock
Jun 28 2024
BUY
Grant, award, or other acquisition
$4,406 $19.94 p/Share
221 Added 1.16%
18,783 Common Stock
Jun 11 2024
SELL
Open market or private sale
$12,882 $22.64 p/Share
569 Reduced 2.97%
18,562 Common Stock
Dec 08 2023
BUY
Grant, award, or other acquisition
-
18,570 Added 50.0%
18,570 Common Stock
PL

Patrick Lamy

Senior VP, Commercial Strategy
South San Francisco, CA

Track Institutional and Insider Activities on AKRO

Follow Akero Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKRO shares.

Notify only if

Insider Trading

Get notified when an Akero Therapeutics, Inc. insider buys or sells AKRO shares.

Notify only if

News

Receive news related to Akero Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on AKRO